C16 3'-sulfo Galactosylceramide (d18:1/16:0)
| Code | Size | Price |
|---|
| TAR-T38179-1mg | 1mg | £1,484.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
C16 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. It is one of the most abundant sulfatides found in porcine brain and plasma. Levels of short-chain sulfatides, including C16-C20 3'-sulfo galactosylceramides, decrease throughout development in mice. C16 3'-sulfo Galactosylceramide inhibits retinal ganglion cell neurite outgrowth in vitro. It is increased in dried urine spots and dried blood spots from patients with metachromatic leukodystrophy (MLD). C16 3'-sulfo Galactosylceramide has been used as an internal standard for the quantification of sulfatides in rat cerebellum and isolated white matter from patients with multiple sclerosis.
CAS:
89771-78-8
Formula:
C40H77NO11S
Molecular Weight:
780.1
Purity:
0.98
SMILES:
O[C@@H]1[C@@H](OS(O)(=O)=O)[C@@H](O)[C@@H](CO)O[C@H]1OC[C@H](NC(CCCCCCCCCCCCCCC)=O)[C@H](O)/C=C/CCCCCCCCCCCCC
References
Saxena K, et al. Unusual hydration properties of C16:0 sulfatide bilayer membranes. Biophys J. 2000 ; 79(1):385-393.
Blomqvist M, et al. In vivo administration of the C16:0 fatty acid isoform of sulfatide increases pancreatic sulfatide and enhances glucose-stimulated insulin secretion in Zucker fatty (fa/fa) rats. Diabetes Metab Res Rev. 2005 ; 21(2):158-166.
Buschard K, et al. The C24:0 Sulfatide Isoform as an Important Molecule in Type 1 Diabetes. Front Biosci (Landmark Ed). 2022 ; 27(12):331.
Buschard K, et al. C16:0 sulfatide inhibits insulin secretion in rat beta-cells by reducing the sensitivity of KATP channels to ATP inhibition. Diabetes. 2006 ; 55(10):2826-2834.
Blomqvist M, et al. Selective lack of the C16:0 fatty acid isoform of sulfatide in pancreas of type II diabetic animal models. APMIS. 2003 ; 111(9):867-877.